Comparison of the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay for detection of high-risk human papillomavirus in women with abnormal PAP smear

摘要: Infection with human papillomavirus (HPV) is a necessary step in the progression to cervical cancer. Many methods for HPV testing are currently available, mostly developed detect pools of types. Hybrid Capture 2 (HC2) one most widely used. A new PCR-based assay, Roche AMPLICOR test, has been recently developed. Both assays recognize group 13 HR types contemporaneously. This study evaluated performance both detecting high-grade lesions as part management abnormal PAP smears. The population was composed 213 women, all referred colposcopy and histologic diagnosis following an test. Biopsy-confirmed intraepithelial neoplasia used gold standard. Overall agreement 84.9% kappa value 0.6. When comparing ability moderate (CIN2+) (CIN3+/cancer), proved slightly more sensitive than HC2, finding that important when triage borderline smear results. Genotyping discordant results showed prevalence LR-HPV HC2 positive/AMPLICOR negative samples, similar HR- positive/HC2 samples. In conclusion, shows assay which makes it valid alternative routine clinical use.